AI Article Synopsis
- Tuberous sclerosis complex (TSC) is a genetic condition causing non-cancerous growths in various organs, including the skin.
- Two patients with TSC and facial angiofibromata were treated with topical and oral rapamycin, resulting in fewer lesions and reduced redness.
- This study is the first to report the effectiveness of topical rapamycin specifically for treating angiofibromata associated with TSC.
Article Abstract
Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous syndrome manifesting as hamartomatous growths in multiple organs. We present two cases of patients with TSC and associated facial angiofibromata treated with topical and oral rapamycin and discuss the role for rapamycin in the treatment of these disfiguring lesions. Our patients demonstrated decreased numbers of angiofibromata and less redness with this treatment. This is the first published report on the use of topical rapamycin for the treatment of angiofibromata.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/09546634.2010.489598 | DOI Listing |
Publication Analysis
Top Keywords
treatment angiofibromata
8
tuberous sclerosis
8
sclerosis complex
8
rapamycin treatment
8
successful treatment
4
angiofibromata
4
angiofibromata tuberous
4
rapamycin
4
complex rapamycin
4
rapamycin tuberous
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!